TSN084 / Tyligand - LARVOL DELTA

The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors (ESMO 2024) - P1 | "TSN084 was well tolerated at doses up to 200 mg and demonstrated preliminary anti-tumor activity in advanced malignant tumors. Further investigations in targeted indications are warranted."

Clinical • Metastases • P1 data • Adenoid Cystic Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AXL

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=74 | Active, not recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Oncology • Solid Tumor

TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2026 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited

Metastases • New P1 trial • Oncology • Solid Tumor

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2025 ➔ Jun 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19 (AACR 2023) - P1 | "TSN084 targets several oncogenic kinases and their drug-resistant mutants. It demonstrated potent antitumor effects in both in vitro and in vivo studies. It showed excellent PK properties and acceptable preclinical safety profile."

Oncology • AXL • DDR1 • FLT3 • NTRK • NTRK3

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited

New P1 trial • Oncology • AXL • MET • NTRK